Study of ONCR-177 Alone and in Combination With PD-1 Blockade in Adult Subjects With Advanced and/or Refractory Cutaneous, Subcutaneous or Metastatic Nodal Solid Tumors or With Liver Metastases of Solid Tumors
- Status
- TERMINATED
- Phase
- PHASE1
Clinical Trials Related to Merck Sharp & Dohme LLC
Related studies linked through entity extraction aliases.
Phase 2 DoceRamPem for Patients With Metastatic or Recurrent NSCLC Who Progressed on Platinum-Doublet and PD-1/PD-L1 Blockade
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Study of SRF617 in Patients With Advanced Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE1
Real-world Evaluation of Bezlotoxumab for the Management of Clostridioides Difficile Infection
- Status
- COMPLETED
- Phase
- N/A
Adjuvant Pembrolizumab vs Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm
- Status
- RECRUITING
- Phase
- PHASE2
A Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL) (MK-3475-A33/KEYNOTE-A33)
- Status
- COMPLETED
- Phase
- PHASE1
Letermovir for the Prevention of Cytomegalovirus Reactivation in Patients With Hematological Malignancies Treated With Alemtuzumab
- Status
- COMPLETED
- Phase
- PHASE2
MK-1942/Donepezil Interactions in Participants With Alzheimer's Disease (MK-1942-005)
- Status
- COMPLETED
- Phase
- PHASE1
Substudy 02B: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With First Line (1L) Advanced Melanoma (MK-3475-02B/KEYMAKER-U02)
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Substudy 02A: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents in Participants With Programmed Cell-death 1 (PD-1) Refractory Melanoma (MK-3475-02A/KEYMAKER-U02)
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Phase 2 Trial for Chemo-Resistant Gestational Trophoblastic Neoplasias With Pembrolizumab (CR-GTP)
- Status
- UNKNOWN
- Phase
- PHASE2
Substudy 02C: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Stage III Melanoma Who Are Candidates for Neoadjuvant Therapy (MK-3475-02C/KEYMAKER-U02)
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Pharmacokinetics of Islatravir in Participants With Severe Renal Impairment (MK-8591-026)
- Status
- COMPLETED
- Phase
- PHASE1
Doravirine/Islatravir (DOR/ISL) in Pediatric Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are <18 Years of Age and Weigh ≥35 kg (MK-8591A-028)
- Status
- COMPLETED
- Phase
- PHASE2
Safety Study of BJ-001, an IL-15 Fusion Protein, for Locally Advanced/Metastatic Solid Tumors
- Status
- UNKNOWN
- Phase
- PHASE1
Use of an Educational Multimedia Tool Versus Routine Care for the Uptake of Postpartum LARC in High-Risk Pregnancies
- Status
- UNKNOWN
- Phase
- NA
Ovarian Function With ENG Implant and UPA Use
- Status
- COMPLETED
- Phase
- EARLY_PHASE1
Pembrolizumab Plus Lenvatinib In Second Line and Third Line Malignant Pleural mesotheLioma Patients
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Cytomegalovirus Infection in Critically Ill Patients and Patients Receiving Anticancer Therapy
- Status
- UNKNOWN
- Phase
- N/A
A Phase Ib Combination Study of Rituximab, TinostamustinEAnd CHeckpoint Inhibition With Pembrolizumab in Relapsed/Refractory DLBCL
- Status
- WITHDRAWN
- Phase
- PHASE1